Atea Pharmaceuticals has already laid off a quarter of its workforce so far this year as the biotech prepares to launch a phase 3 trial of its hepatitis C cocktail. The treatment—a combination ...
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral ...
BOSTON, March 06, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral ...
Shares of Atea Pharmaceuticals stock opened at $2.99 on Friday. Atea Pharmaceuticals has a 12-month low of $2.75 and a 12-month high of $4.18. The company has a market capitalization of $252.54 ...
Atea Pharmaceuticals Inc. reported its Q4 2024 earnings, revealing a wider-than-expected loss per share, which impacted the company’s stock performance. The earnings per share (EPS) came in at ...
The ATEA is equipped with eight vertical electric motors and two horizontal electric motors. The vertical ones, embedded in the wings, kick in to help the aircraft take off and land, while the ...
BOSTON, March 06, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral ...
Atea Pharmaceuticals is actively engaging with investors by hosting a live conference call and audio webcast to report financial results and provide a business update. The company is focused on ...
Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on AVIR: Atea Pharmaceuticals NewsMORE Related Stocks Indices Commodities Currencies Stocks ...
Good afternoon, everyone, and welcome to the Atea Pharmaceuticals' Fourth Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2024 Earnings Call Transcript March 6, 2025 Atea Pharmaceuticals, Inc. misses on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback